Logo do repositório
 
Publicação

Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer

2024-08Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorMedeiros, Mariana Silva
dc.contributor.authorBotelho de Carvalho, Luís André
dc.contributor.authorAlves, Marta
dc.contributor.authorPapoila, Ana
dc.contributor.authorBaptista Carreira dos Santos, Hugo Miguel
dc.contributor.authorCapelo-Martínez, José Luis
dc.contributor.authorPinheiro, Luís Manuel Viegas de Campos
dc.contributor.institutionDQ - Departamento de Química
dc.contributor.pblSpringer Science and Business Media B.V.
dc.date.accessioned2024-10-09T22:39:30Z
dc.date.available2024-10-09T22:39:30Z
dc.date.issued2024-08
dc.descriptionPublisher Copyright: © The Author(s) 2024. Open access funding provided by FCT|FCCN (b-on).
dc.description.abstractPurpose: T1 bladder cancer is known for its high progression and recurrence rates. Identifying aggressive tumours at the non-muscle-invasive stage is crucial to allow early interventions and subsequently increase patient survival. This study aimed to investigate the potential of the cubilin/myeloperoxidase (CUBN/MPO) ratio as a high-grade T1 bladder cancer biomarker. Methods: Urine samples were collected from 30 patients who underwent transurethral resection of the tumour with high-grade T1 bladder cancer (June 2015 to December 2019) before surgery. The urinary proteome was analysed using high-resolution mass spectrometry and the CUBN/MPO ratio was calculated. The primary outcome was the recurrence during the follow-up (around 31.5 months after resection). Univariate Cox regression and Kaplan–Meier curves were used for data analysis. Results: Patients with a low CUBN/MPO ratio exhibited upregulated MPO and/or downregulated CUBN. This group of patients had a higher incidence of disease recurrence and progression. Low CUBN/MPO ratio was significantly associated with a higher likelihood of recurrence, progression, and death. It is worth noting that this study was exploratory and conducted on a small sample size, so further research is needed to validate these findings in larger cohorts. Conclusion: This study highlights the potential of the CUBN/MPO ratio as a prognostic biomarker for high-grade T1 bladder cancer.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent11
dc.format.extent1037765
dc.identifier.doi10.1007/s11255-024-03971-4
dc.identifier.issn0301-1623
dc.identifier.otherPURE: 94071176
dc.identifier.otherPURE UUID: dbcbec7f-d56e-4cdc-8171-6f11ac369851
dc.identifier.otherScopus: 85188991914
dc.identifier.otherWOS: 001191084300003
dc.identifier.otherPubMed: 38530585
dc.identifier.otherPubMedCentral: PMC11266244
dc.identifier.otherORCID: /0000-0002-6032-8679/work/170346746
dc.identifier.urihttp://hdl.handle.net/10362/173273
dc.identifier.urlhttps://www.scopus.com/pages/publications/85188991914
dc.language.isoeng
dc.peerreviewedyes
dc.subjectCUBN/MPO
dc.subjectNon-muscle-invasive bladder cancer
dc.subjectRecurrence
dc.subjectUrinary proteome
dc.subjectNephrology
dc.subjectUrology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleLow Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder canceren
dc.typejournal article
degois.publication.firstPage
degois.publication.lastPage
degois.publication.titleINTERNATIONAL UROLOGY AND NEPHROLOGY
degois.publication.volume56
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Low_Cubilin.pdf
Tamanho:
1013.44 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (FCT)